wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 18. no 2. June 2013  
 TABLE OF CONTENT

 Original articles
Free serum IgE concentration in severe persistent allergic asthma patients during omalizumab therapy. A preliminary study
Ziemowit Ziętkowski, Małgorzata Czarniakowska-Bołtuć, Roman Skiepko, Mateusz Łukaszyk, Anna Bodzenta-Łukaszyk

Introduction. Omalizumab is a humanized monoclonal anti-IgE antibody used in the treatment of patients with severe allergic asthma.
Aim. The aim of this study was to evaluate the concentration of free IgE and omalizumab in serum of patients with severe allergic asthma during treatment with omalizumab.
Materials and methods. The study was conducted in a group of four patients with severe persistent asthma treated with conventional therapy (according to GINA 2006) and further treated with omalizumab. Free IgE and omalizumab serum concentrations were quantified before, after 16 weeks and 6 months of omalizumab therapy using the recoveryELISA (BioTeZ) immunoassay. In addition, all patients at baseline and during treatment with omalizumab were tested for: the severity of symptoms and use of rescue medication; point scale Asthma Control Test (ACT), spirometry parameters, the concentration of exhaled nitric oxide (FENO), blood eosinophil count and serum eosinophil cationic protein (ECP) levels.
Results. Free serum IgE concentration in four of the patients after 16 weeks of starting therapy decreased significantly and remained stable at less than 50 IU/mL after 6 months. Omalizumab concentration in serum of patients after 16 weeks from start of treatment increased. Serum omalizumab concentration in patients after 16 weeks of therapy increased. Reduced severity of clinical symptoms, lower doses of asthma medications and also clinically meaningful improvement in the results of spirometry and exhaled nitric oxide levels were observed in our patients.
Conclusions. Omalizumab therapy results in a significant decrease in the concentration of free IgE in patients showing clinical improvement. The preliminary results suggest that it is advisable to assess the usefulness of this method in monitoring anti-IgE therapy

keywords: astma, omalizumab, wolne IgE, terapia biologiczna, asthma, omalizumab, free IgE, biological therapy

pages: from 110 to 113



estimated time of download (378 kB)
broadband speed:561282565121024[kbps]
time:77251374[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.